Introduction

The liver is the hub of lipid and carbohydrate homeostasis [1]. Disruption of this homeostasis has been implicated in disease processes, such as atherogenesis, insulin resistance, and hypermetabolism [2,3]. Metabolic conditions, such as insulin resistance, may be partly attributable to ‘western-style diets’ and are associated with medical expenditures and lost productivity totaling over $130 billion annually [4]. Therefore, drugs or dietary supplements that could potentially reduce insulin dependence and regulate dyslipidemia could have a dramatic effect on public health.

One group of compounds previously shown to have hypolipidemic and anti-inflammatory properties both in vivo and in vitro are citrus flavonoids [5,6]. The abundant flavonoid aglycone naringenin, which is responsible for the bitter taste in grapefruits, has been extensively studied in recent years. In vivo studies have demonstrated its potential as a normolipidemic agent: in a recent clinical trial, naringenin was shown to reduce circulating levels of low-density lipoprotein (LDL) by 17% in hypercholesterolemic patients [7]. Similarly, the cholesterol-lowering effects of naringenin have been demonstrated in rabbits [8,9] and rats [10]. In HepG2 cells, naringenin was shown to reduce the secretion of VLDL [11,12] through the inhibition of ACAT2 [11] and MTP [13,14], enzymes critical for VLDL assembly. Naringenin was also shown to induce LDL-R transcription through PI3K activation upstream of SREBP-1a [11,14]. Other studies demonstrated that naringenin inhibited HMG CoA reductase (HMGR) [15]. Naringenin’s myriad effects suggest that the flavonoid may be targeting transcriptional regulation of metabolism through nuclear receptors (NRs), a family of ligand-activated transcription factors, which play a critical role in the regulation of lipid metabolism. Strengthening this hypothesis is the anecdotal report that naringenin binds to LXRα [14] and more recently, that the flavonoid induces PPRE activity in U-2OS cells [16].

In this study, we demonstrate that naringenin is an agonist of PPARα and PPARγ, and a partial agonist of LXRα. We show that naringenin induces the activation of PPARα and PPARγ ligand-binding domain (LBD) in GAL4-fusion protein reporters and
induces PPRE activity in Huh7.5 human hepatoma cells. Using an in vitro TR-FRET assay we demonstrate that this interaction does not change the binding of PGC1α co-activator peptide to recombinant PPARα ligand binding domain.

Concomitantly, naringenin inhibits the activation of the LXRα LBD in a GAL4-fusion protein reporter in the presence of the LXRα agonist TO901317. Using an in vitro TR-FRET assay, we demonstrate that this effect is mediated by the inhibition of the binding of the Trap220/Drip-2 co-activator peptide to recombinant LXRα LBD. Expectedly, naringenin also inhibits LXRα activity in Huh7.5 cells. We show that the induction of PPARα and inhibition of LXRα induces the expected transcriptional changes in hepatocytes, upregulating genes important in fatty acid oxidation and down-regulating cholesterol and fatty acid synthesis. These effects result in the induction of a fasted-like state in primary hepatocytes, in which production of triglycerides and bile acids is inhibited and ketone body generation increases.

Results

Naringenin activates PPARα and PPARγ

The manifold effects of naringenin, include the induction of β-oxidation [17] and anti-inflammation [5], suggest an underlying mechanism, similar to the activities of PPARα and PPARγ agonists such as fibrates or thiazolidinediones (TZDs) [18,19]. Therefore, naringenin activation of PPARα and PPARγ were investigated using the previously described HeLa reporter cell lines, HG3LN GAL4-PPARα and HG3LN GAL4-PPARγ [20]. In these cells, the PPAR LBD is fused to the GAL4 DNA binding domain and expressed constitutively. Upon binding to an agonist, the PPAR-GAL4 fusion protein activates a luciferase reporter [20]. Naringenin dose-dependently activated PPARα reaching 24%±0.2% induction at 240 μM (P<0.001) relative to 1 μM of the PPARα agonist GW7647 (Fig. 1a). Furthermore, naringenin activated PPARγ up to 57%±0.3% at 80 μM (P<0.005) relative to the PPARγ agonist 1 μM BRL49653 (Fig. 1b).

To further characterize the interaction between PPARα and naringenin, a Lanthascreen time-resolved fluorescence resonance energy transfer (TR-FRET) assay was performed. This cell-free system measures the ability of a compound to enhance the binding of a recombinant PPARα LBD to a PGC1α co-activator peptide, as measured by an increase in TR-FRET signal. While GW7647 showed a clear dose-dependent increase (EC50 = 2.5nM) in the binding of PGC1α to PPARα as expected (Fig. 1d), the binding of PGC1α to PPARα did not increase in the presence of naringenin (Fig. 1c), suggesting that naringenin’s ability to activate PPARα does not directly involve enhancement of PPARα LBD binding to PGC1α.

One possibility is that naringenin induces the transcription of PGC1α itself, an effect that cannot be seen in the cell-free TR-FRET assay. Indeed, stimulation of Huh7 cells with 380 μM naringenin for 24 hours increased PGC1α mRNA abundance by 14-fold (p = 0.001) compared to DMSO-treated controls.

Naringenin is a partial agonist of LXRα

Our group and others have shown that naringenin inhibits HMGR, an enzyme controlled by SREBP1c and in turn by the LXRα [21,22]. In fact, there are some indications that naringenin binds LXRα in vitro [23]. To test naringenin’s capacity to function as an LXRα antagonist, LXRα-UAS-bla HEK 293T cells were stimulated with 4.7 nM TO901217 (corresponding to TO901317 EC50) and then treated with increasing concentrations of naringenin. Naringenin dose-dependently inhibited LXRα activity, reaching 28.4%±0.4% (p<0.01) and 39.1%±9.4% (p<0.05) at concentrations of 126 μM and 400 μM, respectively (Fig. 2a).

![Figure 1](http://www.plosone.org/attachments/figure1.png)

**Figure 1.** Naringenin induces activation of PPARα and PPARγ ligand-binding domains. HG3LN reporter cells expressing GAL4-PPARα (a) and GAL4-PPARγ (b) reporters were treated with increasing concentrations of naringenin. Naringenin dose-dependently activated PPARα reaching 24%±0.2% induction at 240 μM (P<0.001); and activated PPARγ up to 57%±0.3% at 80 μM (P<0.005). Data is presented as percent activation relative to 1 μM of classical agonists GW7647 and BRL49653, respectively. (c) Lanthascreen TR-FRET assay, demonstrating that naringenin did not affect the binding of the PGC1α co-activator peptide to recombinant PPARα LBD. (d) In contrast, the classical PPARα agonist GW7647 induces a dose-dependent binding of PGC1α to PPARα in the same assay.

doi:10.1371/journal.pone.0012399.g001
The interaction between LXRα and naringenin was further characterized using a Lanthascreen TR-FRET assay. Naringenin enhanced the binding of the LXRα LBD to the Trap 220/Drip-2 co-activator moderately, yet significantly, in a dose-dependent manner reaching 38.0%±2.8% activation (Fig. 2b) compared to the well-studied LXRα agonist, TO901317 (Fig. 2c). Notably, in the presence of 1 μM TO901317 (corresponding to TO901317 EC₅₀), naringenin dose-dependently inhibited the binding of the Trap 220/Drip-2 co-activator to the LXRα LBD, reaching 11.6%±3% inhibition (p<0.01) at 133 μM (Fig. 3d). These results suggest that naringenin is a ligand and a partial agonist of LXRα.

Naringenin induces PPRE and inhibits LXRE activity in hepatocytes

To explore the effect of naringenin on PPAR activation in hepatocytes, we quantified the activation of a PPAR response element (PPRE)-reporter in Huh7 cells. Naringenin treatment significantly and dose-dependently enhanced PPRE activity, reaching 17%±4% (p<0.01) at 150 μM (Fig. 3a). Similar levels of activation were observed when cells were exposed to the known PPAR agonists, WY14,643 (10%±5%) and ciglitazone (24%±5%). Notably, at 200 μM naringenin induction of PPRE was not significantly different than 10 μM WY14,643 (p=0.25).

To test the ability of naringenin to inhibit LXRE activity in hepatocytes, we quantified the activation of LXRE response element (LXRE)-reporter in Huh7 cells. Naringenin treatment significantly and dose-dependently decreased LXRE activity, reaching 50.3%±2.6% inhibition at 150 μM (p<0.001; Fig 3c). By comparison, a recently published LXRE-specific antagonist, 5CPPSS-50 failed to inhibit LXRE activity under the same conditions (Supp. Fig. 1) and led to significant toxicity at higher doses.

Naringenin-induced Gene and Metabolic changes in hepatocytes

To assess if PPARα activation by naringenin leads to induction of PPARα-regulated genes we stimulation Huh7 cells with 200 μM naringenin for 24 hours and quantified mRNA abundance by qRT-PCR. Naringenin induced the expression of fatty acid oxidation genes CYP4A11, ACOX, UCP1 and ApoAI by 68%, 31%, 60%, and 25%, respectively (Fig. 3b). On the other hand, naringenin reduced the mRNA abundance of LXRα-regulated genes ABCA1, ABCG1, HMGR, and FASN by 92%, 27%, 43%, and 41% respectively (Fig. 3d). These results suggest a shift from lipogenesis and cholesterol synthesis to lipolysis.

Interestingly, Huff and coworkers previously demonstrated that naringenin activated SREBP1α-dependent LDLR expression [11,14]. As SREBP is regulated by LXRα we studied the gene expression of SREBP1/2 regulated LDLR and HMGCS promoters in Huh7 cells using reporter constructs. We show that naringenin increases LDLR transcription by 26%±11%, but decreases HMGCS transcription by 13%±3% (Fig 4d). HMGCS is regulated by SREBP2 rather than SREBP1 and like HMGR plays a role in cholesterol synthesis.

ApoB100 is the structural protein of VLDL whose production is blocked by naringenin [21]. As our results suggest that naringenin acts through PPARα induction, we examined whether PPARα and PPARγ agonists, affected ApoB100 secretion. Huh7 cells were stimulated with 200 μM naringenin, 10 μM WY14,643, or 10 μM ciglitazone for 24 hours. Predictably, naringenin led to a 73%±9% (p<0.001) reduction in ApoB production (Fig. 4a).
Figure 3. Naringenin activates PPRE-driven and inhibits LXRE-driven gene expression in human hepatocytes. (a) Naringenin dose-dependently enhanced PPRE activity, in Huh7 cells transiently transfected with a PPRE reporter, reaching 17%±7% (p=0.05) at 200 μM. Induction was not different from PPAR agonists WY14,643 and ciglitazone. (b) Naringenin induced the expression of PPARα coactivator PGC1α by 14-fold (p=0.001) as well as PPARα-regulated fatty acid oxidation genes CYP4A11/22, ACOX, UCP1 and ApoAI. Huh7 cells were treated with naringenin for 24 hours and mRNA isolated and analysed by qRT-PCR. (c) Naringenin dose-dependently suppressed LXRE activity, in Huh7 cells transiently transfected with a LXRE reporter, reaching a 50.3%±2.6% (p<0.001) inhibition at 150 μM. (d) Naringenin inhibited the expression of LXRα-regulated lipogenesis genes ABCA1, ABCG1, HMGR, and FASN. Cell viability under all conditions was greater than 95%.

doi:10.1371/journal.pone.0012399.g003

Figure 4. Naringenin induced a fasted-like state in hepatic lipid metabolism. (a) Huh7 cells were stimulated for 24 hours with 200 μM naringenin, 10 μM WY14,643, or 10 μM ciglitazone. Naringenin treatment led to a 73%±9% (p<0.001) reduction in ApoB production, while WY14,643 led to a 33%±12% (p<0.01) reduction. Treatment with ciglitazone did not lead to a significant change in VLDL production. (b) Primary rat hepatocytes were stimulated with 200 μM naringenin or 10 μM WY14,643. Naringenin treatment led to a 61% (p=0.001) reduction in triglyceride production and 17% increase in ketone body formation, not different from WY14,643. However, naringenin treatment led to a 32%±11% (p=0.005) reduction in bile salt production, while WY14,643 did not. Urea accumulation in the media did not change significantly. (c) Intracellular levels of triglycerides in primary rat hepatocytes stimulated with naringenin. A slight decrease is observed. (d) Naringenin effect on SRE-driven gene expression. We show that naringenin induces LDLR transcription by 26% (p=0.02) while inhibiting HMGCS transcription by 13% (p=0.001). It is thought that each promoter is regulated by a different SREBP isoform.

doi:10.1371/journal.pone.0012399.g004
compared with a 33%±12% (p<0.01) reduction by the PPARα agonist WY14,643. Ciglitazone did not lead to a significant change in ApoB secretion.

Lastly, we characterized the metabolic changes induced by naringenin on primary hepatocytes. Primary rat hepatocytes were stimulated with 200 μM naringenin or 10 μM WY14,643 for 24 hours and culture media was analyzed for changes in urea, triglycerides, bile acid, and ketone bodies (Fig. 4b). As could be expected, primary hepatocytes showed no change in urea production. However, both naringenin and WY14,643 led to a 61 % (p<0.001) and 41 % (p<0.05) reduction in triglyceride production, respectively (Fig. 4b). Ketone body production was only slightly elevated by 17% and 23%, respectively. Importantly, no increase in intracellular levels of triglycerides were found (Fig. 4c) suggesting this inhibition was a result of increased fatty acid oxidation in primary hepatocytes. Interestingly, while PPAR agonists (fibrates) are used to treat hypertriglyceridemia, PPARγ (TZDs) are used to treat type 2 diabetes, naringenin actually decreased the interaction cell-free TR-FRET assay. Interestingly, in the presence of LXR agonist TO901317, naringenin actually decreased the interaction of the Trap-220 co-activator with LXR. The metabolic effect of PPARα and PPARγ using a reporter cell line over expressing GAL4 fusion proteins to either PPARα LBD or PPARγ LBD [20]. Activation of PPAR LBD releases the complex and allows it to bind the UAS, response element, expressing luciferase. This reporter system demonstrates that naringenin acts on the LBD of both PPARα and PPARγ (Fig. 1), suggesting it serves as a natural ligand. However, the TR-FRET assay suggests that naringenin does not induce a conformational change in PPARα LBD like other ligands, such as GW7647, failing to increase its binding to the PGC1α co-activator (Fig. 1). One possibility is that naringenin induces different conformational change in the PPARα LBD that recruits another co-activator, not found in the cell-free TR-FRET assay. However, a more likely scenario is that naringenin induces PPARα phosphorylation or alternately, PGC1α expression. Indeed our data shows that naringenin stimulation increases the mRNA abundance of PGC1α in Huh7 cells by 14-fold. Regardless of the exact nature of the interaction, naringenin-induced PPARα activation, lead to increased PPRE activity in human hepatocytes (Fig. 3a) and the expression of PPARα-regulated genes (Fig. 3b).

Concomitantly with PPARα activation, we show that naringenin inhibits the activity of LXRα. Using a similar reporter cell line over expressing the GAL4 fusion protein with LXRα LBD, we show a significant inhibition of LXRα LBD in the presence of TO901317, a classical agonist (Fig. 2). In contrast to the PPARα findings, we show that naringenin specifically increases the interaction of the Trap-220 co-activator with LXRα LBD in the cell-free TR-FRET assay. Interestingly, in the presence of LXRα agonist TO901317, naringenin actually decreased the interaction of Trap-220 with the LXRα LBD, demonstrating it is a partial agonist of LXRα naturally leading to a competitive inhibition of LXRα activity. This conclusion is further supported by the decrease in LXRα activity in human hepatocytes (Fig 3c) and the down-regulation of LXRα target genes (Fig 3d).

The metabolic effect of PPARα induction and LXRα inhibition by naringenin are shown on gene expression (Fig. 3) and functional levels (Fig. 4). The mRNA abundance of PPARα-target genes that control fatty acid oxidation, such as CYP4A11, ACOX, and UCP1 significantly increases in human hepatoma cells. As lipid metabolism of hepatoma cell lines is dramatically
lower than that of primary hepatocytes, we studied the metabolic aspects of PPARα and LXRα regulation in primary rat hepatocytes. As could be expected, both naringenin and PPARα agonist, WY14,643 led to a similar decrease in triglyceride production and an increase in ketone body secretion (Fig. 4b). Intracellular levels of hepatic triglycerides were also slightly reduced (Fig. 4c). Interestingly, naringenin caused a much steeper 73% decrease in VLDL secretion compared to 33% decrease by WY14,643 (Fig. 4a). This difference was significant (p = 0.006), and could possibly be due to inhibition of cholesterol synthesis through LXRα.

Indeed, the mRNA abundance of LXRα-target genes that regulates fatty acid and cholesterol synthesis, such as ABCA1, ABCG1, HMGCR, and FASN decreases (Fig. 3d). While cholesterol production could not be detected in our system (data not shown), cholesterol serves as the percursor of hepatic bile acids. Interestingly, LXRα activation was shown to drive bile synthesis in rats [24,25]. Therefore, the 32% decrease in bile acids production following naringenin stimulation (Fig. 4b) serves as a surrogate measure of cholesterol production. WY14,643 which upregulates PPARα without effecting LXRα, showed no such change. Regrettably, no reliable LXRα inhibitor is commercially available, and 5CPPSS-50 showed significant toxicity in our hands (Fig. S1). Preliminary results using siRNA to LXRα show some inhibition of bile acid and VLDL production, although results were inconclusive (data not shown).

We note that the GAL4 fusion reporter data suggests that in spite of the well known cross-regulation between PPARα and LXRα [42,43,44], naringenin appears to acts independently on each of these nuclear receptors. This is another indication of the nuclear receptor family promiscuity, and suggests that complex metabolic programs could be induced by relatively few compounds. Indeed, dual PPARα and PPARγ agonists have recently been investigated as normoglycemic and antiatherogenic agents [56]. Naringenin activation of both PPARα and PPARγ suggests a similar ability to regulate insulin sensitivity and LDL levels. However, in contrast to other dual PPAR agonists, such as Aleglitazar, our work shows naringenin is also an LXRα inhibitor. The metabolic program provoked by naringenin, appears to be a fed-to-fasted transition in the lipid metabolism of primary hepatocytes. Naringenin not only increases fatty acid oxidation but also inhibit fatty acid and cholesterol synthesis.

The potential of using a naturally occurring dietary supplement to regulate lipid metabolism is appealing as this by product of the grapefruit juice industry is non-toxic, cheap, and has demonstrated anti-inflammatory properties. This is especially important in the context of the rising costs of cardiovascular care, estimated by the AHA to rise above $500 billion this year. Naringenin ability to inhibit HMGCR, the target of statins, while upregulating PPARα, the target of fibrates, suggest it can naturally find its place in the routine treatment of hyperlipidemia.

Finally, our group and other have shown that the Hepatitis C Virus (HCV) is critically dependent on host lipid metabolism [21,57,58]. Similar interplays were shown for the Hepatitis B Virus (HBV) [39,60]. Therefore, compounds that modulate hepatic lipid metabolism could have significant antiviral effect. And indeed, our work shows that naringenin blocks HCV production from Huh7.5.1/JFH1 infected cells [21]. These findings form the basis of a currently conducted clinical trial to explore naringenin inhibition of HCV production in non-responding patients. Interestingly, the anti-inflammatory properties of naringenin could be readily explained in the context of PPAR activation. Such properties could have a significant effect on liver inflammation, preventing or delaying the development of hepatosteatosis and cancer [61].

Materials and Methods

Reagents

Fetal bovine serum (FBS), phosphate-buffered saline (PBS), Dulbecco’s modified Eagle medium (DMEM), penicillin, streptomycin, trypsin-ethylenediamine tetracetic acid (EDTA), OptiMEM basal medium, and Lipofectamine 2000 were obtained from Invitrogen Life Technologies (Carlsbad, CA). Insulin was obtained from Eli-Lilly (Indianapolis, IN). Dual luciferase assay kit was purchased from Promega (Madison, WI). The reported LXRα antagonist 5CPPSS-50 [62] was a kind gift of Dr. Hashimoto (The University of Tokyo). Unless otherwise noted, all other chemicals were purchased from Sigma-Aldrich Chemicals (St. Louis, MO).

Cell culture

Huh7 cells were a kind gift of Prof. Raymong Chung, Massachusetts General Hospital. The cells were cultured in DMEM supplemented with 10% FBS, and 200 units/mL penicillin and streptomycin in a 5% CO2-humidified incubator at 37°C. Huh7 cells were passaged every 3 days and used at passage <15.

GAL4-nuclear receptor activation assays

Activation of PPAR LBD was quantified using the previously described HGLN5 PPARα and PPARγ cell line [20]. Briefly, HeLa cells were stably transfected with the pGAL4RE/5'-Glob-Luc-SVNeo plasmid, encoding the firefly luciferase gene driven by a pentamer of yeast activator GAL4 binding sites in front of β-globin promoter [20]. Cells were subsequently stably transfected with either pGAL4-PPARα-puro, or pGAL4-PPARγ-puro, encoding amino acids 1–147 of GAL4, followed by a short linker and the LBD of either PPARα or PPARγ, respectively [20]. HGLN5 cells were seeded at a density of 100,000 cells/cm², test compounds were added 8 hours later and incubated for 16 hours. Following treatment, cells were washed with PBS and lysed in 25 mM Tris buffer (pH 7.8). Protein concentration was calculated using the Bradford assay and used to normalize the luciferase activity. Finally, activation of PPARα and PPARγ reporters is presented as percent of maximal activation by the known agonists GW7647 and BRL49653, respectively.

LXRα activation was investigated using the GeneBLAzer Beta-lactamase reporter technology (Invitrogen SelectScreen Cell-Based Nuclear Receptor Profiling Service, Madison, WI). LXR-α/β-As-Aha HEK 293T cells were thawed and resuspended in Assay Media (DMEM phenol red free, 2% CD-treated FBS, 0.1 mM NEAA, 1 mM sodium pyruvate, 100 units/mL penicillin and streptomycin) to a concentration of 312,500 cells/mL. The control agonist TO901317 at the pre-determined EC50 concentration (5 nM) was added to wells containing variable concentrations of naringenin. The plate was incubated for 16–24 hours at 37°C and 5% CO2 in a humidified incubator. Substrate loading solution was added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. Results for each concentration (n = 4) are reported as percent activation of TO901317-stimulated, naringenin-free controls.

TR-FRET Assays

LanthaScreen TR-FRET Coactivator Assays, purchased from Invitrogen (Madison, WI), were used to identify agonists and antagonists of PPARα and of LXRα. In these cell-free assays, ligands are identified by their ability to bind the recombinant LBD of the respective receptor and induce a conformational change that results in recruitment of a fluorescein-labeled.
coactivator peptide. A purified, glutathione S-transferase (GST)-tagged PPAR alpha or LXRα LBD is indirectly labeled using a terbium-labeled anti-GST tag antibody. Recruitment of fluo-
rescein-labeled coactivator peptide – PGC1α for PPARα or Trap220 for LXRα – is measured by monitoring fluorescence resonance energy transfer (FRET) from the terbium-labeled antibody to the fluorescein on the peptide, resulting in a high TR-FRET ratio (520/490 nm emission). Test compounds were diluted in DMSO, and assays were run per the manufacturer’s instructions. Briefly, to test the ability of a molecule to function as an agonist, increasing concentrations of naringenin or control agonist were added to LBD and co-activator peptide solutions. To test the ability of a molecule to function as an antagonist, a similar protocol was followed, but 250 nM TO901317 (EC80 of the agonist, measured in this assay) was added to all wells. In both agonist and antagonist modes, following a 2-hour incubation at room temperature, the 520/490 TR-FRET ratio was measured with a PerkinElmer Envision fluorescence plate reader with TR-FRET laser excitation using the following filter set: excitation 330 nm, emission 495 nm, and emission 520 nm. A 100 μsec delay followed by a 200 μsec integration time was used to collect the time-resolved signal. Results are displayed as percent activation compared to maximal activation of positive control.

PPAR and LXRα response element luciferase reporter assays

Activation of PPRE and LXRE was quantified by transiently transfecting HuH7 cells with previously described firefly luciferase reporter plasmids, pACOX×2luc and pDR4×2luc, respectively [44,63]. The pRL-TK plasmid (Promega, Madison, WI), constitutively expressing renilla luciferase, was co-transfected as positive control. pACOX×2luc was transfected into HuH7 cells cultured in OptiMEM. After 22 hours of culture, cells were stimulated with naringenin, WY14,643, or ciglitizone for 24 hours in standard culture medium. To quantify LXRE activity, cells were similarly transfected and treated with 24 hours in standard culture medium. To quantify LXRE and PPRE activation, the HuH7 cell line was transfected with the firefly luciferase reporter plasmid pACOX×2luc and the renilla luciferase reporter plasmid pRL-TK (Promega, Madison, WI), according to the manufacturer’s instructions. DMSO levels were equal in all samples and never exceeded 0.5%. Results are reported as percent activation compared to DMSO-only controls.

Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)

Following a 24-hour stimulation, cells were lysed with RLT Plus buffer containing β-mercaptoethanol and RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA). Total RNA was quantified on a ND-1000 spectrophotometer (NanoDrop Technologies, Rockland, Del.) and mRNA transcript abundance was measured on a ABI Prism 7300 Real-Time PCR Detection System using iScript One-Step RT-PCR Kit With SYBR Green (Bio-Rad, Hercules, CA), according to the manufacturer’s instructions. Primers used in these reactions (Integrated DNA Technologies, Coralville, IA) were designed using the PRIMER-BLAST program and appear in Table 1.

Human ApoB Enzyme-Linked Immunosorbent Assay (ELISA)

HuH7-secreted ApoB-100 was detected using ALerCHEK, Inc. (Portland, ME), total human ApoB-100 ELISA kit. The medium was diluted 1:10 with the specimen diluent, and the assay was carried out according to the manufacturer’s directions.

Analysis of metabolic changes in primary rat hepatocytes

Primary rat hepatocytes were harvested from adult female Lewis rats purchased from Charles River Laboratories, as previously described [64]. All animals were treated in accordance with the National Research Council guidelines and approved by the Subcommittee on Research Animal Care at the Massachusetts General Hospital (IACUC #2005N000109). Cells were seeded on collagen-coated dishes at a density of 150,000 cells/cm² under serum-free conditions, using 100 μM esmolol, a beta-blocker, as an attachment factor. Serum-free hepatocyte culture medium was purchased from Lonza (Walkersville, MD). Cells were stimulated with naringenin or WY14,643 for 24 hours, and cell culture medium was collected for metabolic analysis. Cell pellet was collected for intracellular triglyceride and total protein determination.

Urea concentration was measured using diacetylmonoxime methodology using a commercial available Blood Urea Nitrogen kit (Stanbio Labs, Boerne, TX). Triglycerides, in the culture medium and cell extracts, were quantified using a commercial kit (Sigma Chemical, St.Louis, MO) based on enzymatic hydrolysis by lipase to glycerol. Ketone bodies, were measured based on the appearance of NADH in conversion to acetoacetate in presence of b-hydroxybutyrate dehydrogenase (Zupke et al.1998). Total cholesterol was measured by a commercial available kit (StandBio Labs) based on the reaction of free cholesterol and cholesterol esters with cholesterol oxidase. Bile acids were determined through the formation of NADH in presence of the enzyme 3-α-hydroxysteroid dehydrogenase (Bio-Quant, San Diego, CA).

Table 1. Real-Time qRT-PCR Primers.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primers</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPARα</td>
<td>ACG CTG TCA CCA GCT TCG AG</td>
</tr>
<tr>
<td></td>
<td>GAA AGA AGC CCT TGC AGC CT</td>
</tr>
<tr>
<td>CYP4A11/22</td>
<td>ACT GCC TCT TCG GGC ACA TC</td>
</tr>
<tr>
<td></td>
<td>ACA CGA ACT TTG CTC CCC CA</td>
</tr>
<tr>
<td>ACOX</td>
<td>TGG CAC ATA CGT GAA ACC GC</td>
</tr>
<tr>
<td></td>
<td>CGC TGT ATC GGA TGG CAA TG</td>
</tr>
<tr>
<td>ApoAI</td>
<td>AAA GCT GCG GTG CCT ACC TT</td>
</tr>
<tr>
<td></td>
<td>CGC TGT CTT TGA GCA CAT CCA</td>
</tr>
<tr>
<td>LXRα</td>
<td>GCT CTT TTC CTG ACC GCC TT</td>
</tr>
<tr>
<td></td>
<td>TGA ATT CCA CTT GCA GCC CT</td>
</tr>
<tr>
<td>ABCA1</td>
<td>TCT GGA AAG CTC TGA AGC CG</td>
</tr>
<tr>
<td></td>
<td>TGA GTT CCT CCC ACA TGC TT</td>
</tr>
<tr>
<td>ABCG1</td>
<td>ACC GGG GAA AAG TCT GCA AT</td>
</tr>
<tr>
<td></td>
<td>TCA CGC GCC GAC TGT CTA GA</td>
</tr>
<tr>
<td>HMGR</td>
<td>GAC CCC TTT GCT TAG ATG AA</td>
</tr>
<tr>
<td></td>
<td>GGA CTG GAA AGC GAT AIA AA</td>
</tr>
<tr>
<td>FASN</td>
<td>TTG CAG GGA GAC CTG ATG AT</td>
</tr>
<tr>
<td></td>
<td>GGT GAG GGT GCT CAT AAC AG</td>
</tr>
<tr>
<td>PGC1α</td>
<td>GGC AGA AGA GCC GTC TCT ACT TA</td>
</tr>
<tr>
<td></td>
<td>TCT GAA TGG TTC TGG GTA CTG A</td>
</tr>
</tbody>
</table>

doi:10.1371/journal.pone.0012399.t001
Statistics
Data are expressed as the mean ± standard deviation. Statistical significance was determined by a one-tailed Student’s t-test. A P-value of 0.05 was used for statistical significance.

Supporting Information
Figure S1  5CPPSS-50 led to no change in LXRE activity. In all experiments, Renilla luciferase was used to account for variability in transfection efficiencies. Found at: doi:10.1371/journal.pone.0012399.s001 (3.87 MB TIF)

References

Acknowledgments
The authors wish to thank Candice Calhoun for technical assistance, Prof. Raymond T. Chung and Dr. Alejandro Soto-Gutierrez for important discussion.

Author Contributions
Conceived and designed the experiments: JG YN. Performed the experiments: JG PYC EY PB YN. Analyzed the data: JG PYC YN. Contributed reagents/materials/analysis tools: PB MLY YN. Wrote the paper: JG YN.

Naringenin: PPARα and LXRx
liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Molecular Endocrinology 17: 1240–1254.


